Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition with Sunitinib

Hypertension

Volumn 66, Issue 3, 2015, Pages 543-549

  Lankhorst, Stephanie ^a   Baelde, Hans J ^b   Kappers, Mariëtte H W ^a,c   Smedts, Frank M M ^a,d   Hansen, Alastair ^e   Clahsen Van Groningen, Marian C ^a   Sleijfer, Stefan ^f   Mathijssen, Ron H J ^f   Danser, A H Jan ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

^d REINIER DE GRAAF HOSPITAL   (Netherlands)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

endothelin 1; hypertension; proteinuria; sunitinib; vascular endothelial growth factor A

Indexed keywords

CYSTATIN C; CYTOCHROME P450 3A4; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; NEPHRIN; NEPHRIN 1; PODOCIN; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; VASCULOTROPIN A;

ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; ELECTRON MICROSCOPY; GENE EXPRESSION; GLOMERULAR ENDOTHELIOSIS; GLOMERULAR FILTRATION BARRIER; GLOMERULOPATHY; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY ISCHEMIA; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NEPHROTOXICITY; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; TELEMETRY; URINARY EXCRETION; WISTAR KYOTO RAT; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; KIDNEY DISEASE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; KIDNEY; KIDNEY DISEASES; MALE; PODOCYTES; PROTEIN KINASE INHIBITORS; PYRROLES; RATS; RATS, INBRED WKY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84939237478     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05435     Document Type: Article

References (32)

1. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of antitumour activity. Nat Rev Cancer. 2008;8:579-591. doi: 10.1038/nrc2403.
2. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-1795. doi: 10.1038/ sj.bjc.6603813.
3. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens. 2013;31:444-54; discussion 454. doi: 10.1097/HJH.0b013e32835c1d1b.
4. Eechoute K, van der Veldt AA, Oosting S, Kappers MH, Wessels JA, Gelderblom H, Guchelaar HJ, Reyners AK, van Herpen CM, Haanen JB, Mathijssen RH, Boven E. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 2012;92:503-510. doi: 10.1038/clpt.2012.136.
5. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136. doi: 10.1056/NEJMoa0707330.
6. Vigneau C, Lorcy N, Dolley-Hitze T, Jouan F, Arlot-Bonnemains Y, Laguerre B, Verhoest G, Goujon JM, Belaud-Rotureau MA, Rioux-Leclercq N. All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study. Nephrol Dial Transplant. 2014;29:325-332. doi: 10.1093/ndt/gft465.
7. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658. doi: 10.1172/ JCI17189.
8. Kappers MH, Smedts FM, Horn T, van Esch JH, Sleijfer S, Leijten F, Wesseling S, Strevens H, Jan Danser AH, van den Meiracker AH. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system. Hypertension. 2011;58:295-302. doi: 10.1161/ HYPERTENSIONAHA.111.173559.
9. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56:675-681. doi: 10.1161/ HYPERTENSIONAHA.109.149690.
10. Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C, Camussi G. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol. 2008;294:F1185-F1194. doi: 10.1152/ ajprenal.00442.2007.
11. Buelli S, Rosanò L, Gagliardini E, Corna D, Longaretti L, Pezzotta A, Perico L, Conti S, Rizzo P, Novelli R, Morigi M, Zoja C, Remuzzi G, Bagnato A, Benigni A. arrestin-1 drives endothelin-1-mediated podocyte activation and sustains renal injury. J Am Soc Nephrol. 2014;25:523-533. doi: 10.1681/ASN.2013040362.
12. Lankhorst S, Kappers MH, van Esch JH, Smedts FM, Sleijfer S, Mathijssen RH, Baelde HJ, Danser AH, van den Meiracker AH. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study. Hypertension. 2014;64:1282-1289. doi: 10.1161/HYPERTENSIONAHA.114.04187.
13. de Bruijn P, Sleijfer S, Lam MH, Mathijssen RH, Wiemer EA, Loos WJ. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2010;51:934-941. doi: 10.1016/j.jpba.2009.10.020.
14. Koop K, Eikmans M, Wehland M, Baelde H, Ijpelaar D, Kreutz R, Kawachi H, Kerjaschki D, de Heer E, Bruijn JA. Selective loss of podoplanin protein expression accompanies proteinuria and precedes alterations in podocyte morphology in a spontaneous proteinuric rat model. Am J Pathol. 2008;173:315-326. doi: 10.2353/ajpath.2008.080063.
15. Yu H, Steeghs N, Kloth JS, de Wit D, van Hasselt JG, van Erp NP, Beijnen JH, Schellens JH, Mathijssen RH, Huitema AD. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662. Br J Clin Pharmacol. 2015;79:809-819. doi: 10.1111/ bcp.12550.
16. Lankhorst S, Kappers MH, van Esch JH, Danser AH, van den Meiracker AH. Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress. Antioxid Redox Signal. 2014;20:135-145. doi: 10.1089/ars.2013.5244.
17. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49:186-193. doi: 10.1053/j.ajkd.2006.11.039.
18. Speed B, Bu HZ, Pool WF, Peng GW, Wu EY, Patyna S, Bello C, Kang P. Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans. Drug Metab Dispos. 2012;40:539-555. doi: 10.1124/dmd.111.042853.
19. Müller-Deile J, Schiffer M. Renal involvement in preeclampsia: similarities to VEGF ablation therapy. J Pregnancy. 2011;2011:176973. doi: 10.1155/2011/176973.
20. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707-716. doi: 10.1172/JCI17423.
21. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683. doi: 10.1056/NEJMoa031884.
22. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A, Kalluri R. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem. 2003;278:12605-12608. doi: 10.1074/ jbc.C300012200.
23. Hara A, Wada T, Furuichi K, Sakai N, Kawachi H, Shimizu F, Shibuya M, Matsushima K, Yokoyama H, Egashira K, Kaneko S. Blockade of VEGF accelerates proteinuria, via decrease in nephrin expression in rat crescentic glomerulonephritis. Kidney Int. 2006;69:1986-1995. doi: 10.1038/ sj.ki.5000439.
24. Schrijvers BF, Flyvbjerg A, De Vriese AS. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int. 2004;65:2003-2017. doi: 10.1111/j.1523-1755.2004.00621.x.
25. Advani A, Kelly DJ, Advani SL, Cox AJ, Thai K, Zhang Y, White KE, Gow RM, Marshall SM, Steer BM, Marsden PA, Rakoczy PE, Gilbert RE. Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions. Proc Natl Acad Sci U S A. 2007;104:14448-14453. doi: 10.1073/pnas.0703577104.
26. Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H, Kalluri R, Grande JP. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant. 2007;22:1136-1143. doi: 10.1093/ ndt/gfl711.
27. Veron D, Reidy KJ, Bertuccio C, Teichman J, Villegas G, Jimenez J, Shen W, Kopp JB, Thomas DB, Tufro A. Overexpression of VEGF-A in podocytes of adult mice causes glomerular disease. Kidney Int. 2010;77:989-999. doi: 10.1038/ki.2010.64.
28. Liu G, Kaw B, Kurfis J, Rahmanuddin S, Kanwar YS, Chugh SS. Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J Clin Invest. 2003;112:209-221. doi: 10.1172/JCI18242.
29. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N Engl J Med. 2006;354:1387-1401. doi: 10.1056/NEJMra052131.
30. Star GP, Giovinazzo M, Lamoureux E, Langleben D. Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro. Life Sci. 2014;118:191-194. doi: 10.1016/j.lfs.2014.02.032.
31. Saleh MA, Pollock JS, Pollock DM. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J Pharmacol Exp Ther. 2011;338:263-270. doi: 10.1124/jpet.111.178988.
32. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension. 2010;56:942-949. doi: 10.1161/ HYPERTENSIONAHA.110.156570.